Report overview
Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. A number of types of pancreatic cancer are known. The most common, pancreatic adenocarcinoma, accounts for about 90% of cases, and the term "pancreatic cancer" is sometimes used to refer only to that type. These adenocarcinomas start within the part of the pancreas that makes digestive enzymes. Several other types of cancer, which collectively represent the majority of the no adenocarcinomas, can also arise from these cells. About 1-2% of cases of pancreatic cancer are neuroendocrine tumors, which arise from the hormone-producing cells of the pancreas. These are generally less aggressive than pancreatic adenocarcinoma.
This report aims to provide a comprehensive presentation of the global market for Pancreatic Cancer Diagnostic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pancreatic Cancer Diagnostic. This report contains market size and forecasts of Pancreatic Cancer Diagnostic in global, including the following market information:
Global Pancreatic Cancer Diagnostic Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Pancreatic Cancer Diagnostic market was valued at US$ 5879.4 million in 2022 and is projected to reach US$ 9432.5 million by 2029, at a CAGR of 7.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Pancreatic Cancer Diagnostic main manufactuers include Siemens, GE Healthcare, Roche, Philips Healthcare, totally accounting for 15% of the market. North America is the largest market, with a share about 40%. As for the types of products, it can be divided into imaging, tumor biomarker, biopsy and others. The most common type is imaging, with a share over 63%. As for the types of applications, it is widely used in hospitals, clinics and others. The most common application is in hospitals, with a share over 45%.
We surveyed the Pancreatic Cancer Diagnostic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pancreatic Cancer Diagnostic Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Pancreatic Cancer Diagnostic Market Segment Percentages, by Type, 2022 (%)
Imaging
Tumor Biomarker
Biopsy
Others
Global Pancreatic Cancer Diagnostic Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Pancreatic Cancer Diagnostic Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Pancreatic Cancer Diagnostic Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Pancreatic Cancer Diagnostic Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pancreatic Cancer Diagnostic revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Pancreatic Cancer Diagnostic revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Siemens
GE Healthcare
Roche
Philips Healthcare
Danaher
Canon Medical Systems
Abbott
Hitachi Medical
Qiagen
Myriad Genetics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Pancreatic Cancer Diagnostic, market overview.
Chapter 2: Global Pancreatic Cancer Diagnostic market size in revenue.
Chapter 3: Detailed analysis of Pancreatic Cancer Diagnostic company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pancreatic Cancer Diagnostic in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
